TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03997812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injections
Description: IV infusion of 1000 mg of VVZ-149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of 0 mg of VVZ-149
Study: NCT04594681

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered once daily or three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4951
Description: KHK4951 is administered once daily or three times daily.
Study: NCT03918629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile
Description: Toxoid-based Clostridium difficile vaccine
Study: NCT03470337

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02953899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: In addition to Cognitive Behavioural Therapy, this intervention uses small incentives to reinforce study attendance and gambling abstinence.
Study: NCT02158845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS: levonorgestrel intrauterine system
Description: LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRHa: leuprolide
Description: 3.75 mg leuprolide injected intramuscularly on a monthly basis
Study: NCT03918629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline solution (0.9% sodium chloride)
Study: NCT02862002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic education of type caratif
Description: study the effects of a therapeutic education program type caratif, based on a communication pedagogy, with the patient receiving opioid therapy in medical oncology

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic education of type caratif
Description: study the effects of a therapeutic education program type caratif, based on a communication pedagogy, with the patient receiving opioid therapy in medical oncology
Study: NCT01324778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed TX
Description: OsseoSpeedTM TX implants of lengths 6-17 mm
Study: NCT02862002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: patients receiving standard care of cancer pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: patients receiving standard care of cancer pain.
Study: NCT03592251

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive Oil Placebo
Description: 6 months placebo supplementation
Study: NCT02953899

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: This intervention uses psychoeducation, behavioural strategies, and cognitive restructuring to assist the participant in their efforts to become abstinent from gambling.
Study: NCT01324778

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OsseoSpeed
Description: OsseoSpeedTM implants of lengths 6-17 mm
Study: NCT03592251

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive Oil Placebo
Description: 6 months placebo supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA-rich
Description: 6 months placebo supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EPA-rich
Description: 6 months placebo supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA-rich
Description: 6 months placebo supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: DHA-rich
Description: 6 months placebo supplementation
Study: NCT02756182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDOC air-charged catheter
Description: Urodynamic study utilizing a single catheter technique to measure WP \& AC measurements
Study: NCT04570033

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: We assessed sensitivity of 18F-FCH PET/CT in preoperative localisation of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism
Description: We prospectively enrolled 65 consecutive patients with PHPT who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study. PET/CT scans were performed 65.0 ± 13.3 min after injection of 218.5 ± 31.9 MBq of 18F-fluorocholine (FCH). Three experienced nuclear medicine physicians assessed the detection rate of hyperfunctioning parathyroid tissue. Response to parathyroidectomy and clinical follow-up served as a reference test. Per-patient sensitivity and positive predictive value (PPV) were calculated for patients who underwent surgery.
Study: NCT05003765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg
Description: Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate as adjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg
Description: Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate and 300 mcg buprenorphine as adjuvants.
Study: NCT01723358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: The intervention will consist of a period of treatment with NMES. This treatment will involve 20-45 minute feeding therapy sessions during which NMES will be administered by an Occupational Therapist. Frequency of therapy sessions will be 4 times per week for the first 2 weeks (as in inpatient, if hospitalized) and then biweekly for 14 weeks for a total of 36 sessions (over 16 weeks). For patients who are discharged prior to the first 2 weeks of treatment, outpatient sessions will be biweekly.
Study: NCT03990012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IR Imaging
Description: Subjects will undergo steady steady state and video IR imaging of the breasts.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Scanning
Description: Subjects will undergo 3D scanning of the breasts.
Study: NCT02433015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: eGo-type electronic cigarette with a supply of 18mg/ml nicotine solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Cigarette
Description: Smoke own brand of cigarette as previously
Study: NCT05767112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplement administation
Description: HMB was administred in 3 different forms: 1) HMB-FA in clear capsules; 2) HMB-Ca in gelatine capsules; 3) HMB-Ca dissolved in water. All treatments provided 1g of HMB. Blood samples were taken before and on multiple time points following ingestion.
Study: NCT01959139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Description: 3 ug/kg on Day 1, IV over 15 minutes
Study: NCT00329706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET brain scan
Description: The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDG-PET brain scan
Description: The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
Study: NCT03377712

Intervention type: DEVICE
Intervention: optoelectronic plethysmography
Description: Evaluates the thoracoabdominal kinematics and the ventilatory pattern of the patient through the filming with cameras, simple and non-invasive examinations

Intervention type: DEVICE
Intervention: optoelectronic plethysmography
Description: Evaluates the thoracoabdominal kinematics and the ventilatory pattern of the patient through the filming with cameras, simple and non-invasive examinations

Intervention type: DEVICE
Intervention: diaphragmatic ultrasound
Description: Evaluates the diaphragmatic mobility through images, simple and non-invasive use
Study: NCT01927120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Orally on day -1. The dose for loading is 12 mg by mouth (PO)
Study: NCT01437293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa / carbidopa / entacapone (LCE)
Description: For this trial we propose a target dosage of L-dopa / carbidopa / entacapone of 400 mg L-dopa / 100mg carbidopa / 200 mg entacapone, twice daily.
Study: NCT04133857

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: aerobic exercise HIIT : High intensity interval training SSMIT : Steady state moderate intensity training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: aerobic exercise HIIT : High intensity interval training SSMIT : Steady state moderate intensity training
Study: NCT01930682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early post-fibrinolytic catheterisation
Description: Early post-fibrinolytic catheterisation after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary PCI
Description: For STEMI Patients,primary PCI is performed within 12 hours after the onset.
Study: NCT04545840

Intervention type: DEVICE
Intervention: Dental Implants
Description: Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
Study: NCT01424007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: Participants would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: Participants would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: Participants would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
Study: NCT03642197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attendance
Description: The SFA and PA arms will be instructed to attend pre-surgery classes and clinical visits with the patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attendance
Description: The SFA and PA arms will be instructed to attend pre-surgery classes and clinical visits with the patients.
Study: NCT00870844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA24493 (CEPO)
Description: 0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA24493 (CEPO)
Description: 0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA24493 (CEPO)
Description: 0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vials with solution for IV infusion
Study: NCT00469924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real Time Clinical Alerting
Study: NCT04720105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duobrii®
Description: Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) will be provided at weeks 0,2,8,16 for a total of 24 weeks.
Study: NCT03500198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL
Description: Intraocular lens replaces the natural lens removed during cataract surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Monofocal Intraocular Lens: TECNIS Monofocal IOL
Description: Intraocular lens replaces the natural lens removed during cataract surgery.
Study: NCT05271175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active intermittent theta burst stimulation
Description: An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active intermittent theta burst stimulation
Description: An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intermittent theta burst stimulation
Description: An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil. The MagVenture Cool-B65 Active/Placebo (A/P) coil is designed to support true double blinded clinical trials as it can produce active and placebo stimulation by flipping the coil and can mimic tapping sensation during placebo condition During the sham condition, the coil produced the same sound as the real active condition but did not deliver any stimulation on the side of the participant's skull.
Study: NCT01060241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Intervention
Description: The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
Study: NCT02279966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Paroxetine 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04459039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000 mL 0.9% sterile saline
Description: Within 12 h of surgery, the experimental group received 1000 mL 0.9% sterile saline intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 250 mL 0.9% sterile saline
Description: Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously.
Study: NCT01891864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP2015 Etanercept
Description: Sandoz has developed GP2015 Etanercept (Sandoz's code for the drug product containing the active ingredient etanercept) to be biosimilar to Enbrel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel
Description: Enbrel is used as reference product to GP2015.
Study: NCT03593837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huang qi gui zhi wu wu granule
Description: Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huang qi gui zhi wu wu granule placebo
Description: Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
Study: NCT01092130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2000 IU vitamin D daily, for 6 weeks
Study: NCT01616992

Intervention type: DRUG
Intervention: Bupivacaine
Description: 20 ML dose of 0.75% Bupivacaine Instillation (into bladder) 1 time during second study visit.
Study: NCT01959139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Description: 3 ug/kg on Day 1, IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2, on Day 2, IV over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m\^2, on Day 2, IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2, on Day 2, IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2, on Day 2, IV over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 400 mg/m\^2, on Day 2, IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2, on Day 2, IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m\^2, on Day 2, IV over 1.5 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m\^2, on Day 2, IV over 1.5 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m\^2, on Day 2, IV over 1.5 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 2,400 mg/m\^2, Days 2-4, IV over 46 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 2,400 mg/m\^2, Days 2-4, IV over 46 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 2,400 mg/m\^2, Days 2-4, IV over 46 hours
Study: NCT01900587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER Tamper-resistant Formulation (TRF)
Description: Single dose of tapentadol ER 50 milligram (mg), will be administered under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER Tamper-resistant Formulation (TRF)
Description: Single dose of tapentadol ER 50 milligram (mg), will be administered under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER Prolonged-Release 2 (PR2)
Description: Single dose of tapentadol ER 50 milligram (mg), prolonged release tablet will be administered under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER Prolonged-Release 2 (PR2)
Description: Single dose of tapentadol ER 50 milligram (mg), prolonged release tablet will be administered under fasted condition.
Study: NCT01819896

Intervention type: DRUG
Intervention: Pacemaker and defibrillator
Study: NCT02173171

Intervention type: OTHER
Intervention: Information collection
Description: Q3M Information collection
Study: NCT03154996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan is a chemotherapeutic agent that is a topoisomerase inhibitor. TPT is administered through an externalized catheter and external microinfusion pump.~Dose: 146 micrometers (uM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Gadolinium is a widely available MRI contrast agent that is used routinely in clinical practice via IV administration, especially for imaging of intracranial tumors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synchromed II infusion pumps
Description: Implanted subcutaneously to facilitate chronic infusion.
Study: NCT02270554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endo GIA Reinforced Reload with Tri-Staple technology
Description: Device:Endo GIA Reinforced Reload with Tri-Staple technology
Study: NCT05833997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar Transurethral resection of bladder tumor
Description: Patients randomized to Monopolar TURBT will be operated using a 26F continuous-flow resectoscope sheaths and a single-pole working element to exclusive use of the resection. The power will be set to cut in 80w and 60w. The technique that will be performed will be the classic endoscopic resection from the top of the tumor until reaching the base, taking a sample from the base of the lesion (muscle layer). Fragments will be removed through an Ellik evacuator, and the solution used will be 3% glycine. After the procedure, the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation.~After 30-60 days of the first procedure, all patients diagnosed with a lamina propria invasion in the uro-pathology analysis (T1) will be submitted to a new monopolar TURBT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holmium Laser resection of bladder tumor (HoLEBT)
Description: It will be used a 24-26F continuous-flow resectoscope sheath with a specific working element to use with a 600µm fiber to Laser Holmium.~Patients will be operated with the Megapulse 70w (Richard Wolf) and laser will be set to deliver the energy of 0,5J and 30-40Hz frequency, 15-20W of final energy. The solution used will be 0,9% saline solution. The resection will start from the base of the lesion, reaching the muscle layer to obtain a sample and resection of the whole tumor, without fragmentation. After this, the morcellation will be performed in the apex of tumor sparing the base with a long nephroscope, and the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation. The morcellated product will be sent to the pathology lab for detailed analysis.